Shares of Inovio Pharmaceuticals Inc. INO jumped 12.11% to $2.13 Wednesday, on what proved to be an all-around mixed trading ...

This was the stock's fourth consecutive day of losses.

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Inovio (INO) announced that peer-reviewed data from its Phase 1/2 clinical trial with INO-3107 as a potential treatment for recurrent ...

Shares of NASDAQ INO opened at $1.98 on Friday. The company has a market capitalization of $51.68 million, a PE ratio of -0.95 and a beta of 0.84. Inovio Pharmaceuticals has a twelve month low of ...

24 Jan 2025 14:16:57 GMT Inovio Pharmaceuticals, Inc. (INO) shares plummeted 28.34% Monday after the biotech company announced that the U.S. Food and Drug Administration (FDA) had put its COVID-19 ...

Nasdaq provides an interactive stock information chart to view history. Downloadable stock history data table is also accessible by clicking on Data Table on the navigation tool bar. If you have ...

View Our Latest Stock Report on INO Inovio Pharmaceuticals Trading Down 0.5 % NASDAQ INO opened at $1.86 on Wednesday. The company’s fifty day simple moving average is $3.19 and its 200-day ...

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...